← All trials
NCT04341454
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2020
- Primary completion
- Feb 19, 2021
- Completion date
- Dec 31, 2021
- First posted
- Apr 10, 2020
- Last posted
- Apr 13, 2020
- Enrollment
- 327
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Daewoong Pharmaceutical Co. LTD.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.